FDA Clearance Tracker · P170011-S047
Impella RP, Impella RP with SmartAssist
Last checked: Nov 20, 2026Latest source record: Dec 5, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 5, 2022
Approved
Time to decision
32 days
Received Nov 3, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170011-S047
- Device name
- Impella RP, Impella RP with SmartAssist
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Nov 3, 2022
- Decided
- Dec 5, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P170011
Device type
- Device class
- Class III
- Regulation
- 21 CFR 870.4360
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for various modifications to the Instructions for Use to add the final results of Post-Approval Study (PAS) #1, Impella RP Real-World Evidence Evaluation and Periodic Reporting and to update the indications for use statement based on the PAS results.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.